Twitter | Search | |
PRECIS-2
PRECIS-2 tool: to design trials that are fit for purpose. Helping trialists consider the impact design decisions have on applicability of results
233
Tweets
222
Following
392
Followers
Tweets
PRECIS-2 Jun 25
Fantastic news! Thanks for letting us know 😊
Reply Retweet Like
PRECIS-2 retweeted
HSRU Jun 24
PAPER: Check out the new paper in from Kevin Thorpe & our outlining thoughts on the role of PRECIS-2 for retrospective assessment of RCTs in systematic reviews
Reply Retweet Like
PRECIS-2 retweeted
JAMA Internal Medicine Apr 1
randomized : Has the level of pragmatism in the score changed over 20 yrs?
Reply Retweet Like
PRECIS-2 Jan 11
I agree part of flexibility of delivery and could be part of flexibility of adherence in . It could affect recruitment too! Toronto brainstormers discussed creating a separate domain & as stated before blinding can be in that are largely explanatory or pragmatic.
Reply Retweet Like
PRECIS-2 Jan 10
Great question ! looks at explanatory & pragmatic design choices. Blinding is not a distinguishing feature. You can get an explanatory open label RCT & triple blind pragmatic trial & vice versa. Lots of discussion blinding developing but agreed no
Reply Retweet Like
PRECIS-2 retweeted
Kirsty Loudon Jan 9
Excited to see this in print to round off 2019! Privilege to be part of the team organising and delivering to programme managers helping write grants. Permission to share and copy to help improve trial design round the globe 🌎
Reply Retweet Like
PRECIS-2 retweeted
Mindy Clyne Dec 10
Using PRECIS-2 in the design and evaluation of pragmatic clinical trials of medicine interventions
Reply Retweet Like
PRECIS-2 Dec 12
YES... a moderate increase in the level of pragmatism in CV trials over 2 decades using . Eligibility, setting, intervention delivery, & primary outcome most likely increases. Still evidence gap & need more in but right direction
Reply Retweet Like
PRECIS-2 retweeted
NIH Collaboratory Oct 28
The Living Textbook offers best practices in design, conduct, and reporting of . What’s missing? Please tell us at . The online survey will close this Thursday, 10/31.
Reply Retweet Like
PRECIS-2 retweeted
JAMA Cardiology 1 Sep 19
randomized : Has the level of pragmatism in the score changed over 20 yrs?
Reply Retweet Like
PRECIS-2 retweeted
Kirsty Loudon 27 Aug 19
It’s a new dawn... 🎶 it’s a new day. Workshop with Zoom talking to trial team in Dublin scoring the Pilot &Feasibility study WeCanQuit smoking cessation for women in deprived areas. Hope the dog doesn’t bark!
Reply Retweet Like
PRECIS-2 retweeted
Russ Glasgow 17 Aug 19
Congratulations Maria and team on your new article on Intervention mapping
Reply Retweet Like
PRECIS-2 retweeted
PRECIS-2 25 Jan 19
⁩ Community Oncology Research Program (NCORP) increases the generalizability of study findings,1100 access sites for ALL patients. Modernizing Clinical Trials for Patients With Cancer. | Oncology | JAMA | JAMA Network
Reply Retweet Like
PRECIS-2 retweeted
Shaun Treweek 27 Jun 19
Rory O’Connor: trial eligibility criteria materially affects generalisability. Quite so. has something to offer
Reply Retweet Like
PRECIS-2 retweeted
Iain Chalmers 20 May 19
To mark International Clinical Trials Day 2019 the editorial team of the James Lind Library is publishing a new, free, 100-page book entitled 'The James Lind Library's Introduction to Fair Tests of Treatments'. We hope you enjoy it. Best wishes!
Reply Retweet Like
PRECIS-2 retweeted
Miles Witham 18 May 19
Not an algorithm as such, but the PRECIS-2 toolkit can help you decide where on the pragmatic-explanatory spectrum your trial design sits, and thus helps to design a trial that is appropriate for the question you seek to answer.
Reply Retweet Like
PRECIS-2 7 Mar 19
Replying to @EpiEllie
So you’ve got an intervention worked up in pilot and problem solved test out in and participants really like and self motivated so you’d have low drop out and high adherence. It’s all about the intervention design - why would design be a problem?
Reply Retweet Like
PRECIS-2 7 Mar 19
Replying to @EpiEllie
Hi, wondered what empirical basis is for increased loss to follow up and lack of adherence in -trials, noticed you referenced ​Hernán’s 2013 paper for loss to follow up interesting choice - RCTs analysed as observational studies. could you explain?
Reply Retweet Like
PRECIS-2 25 Jan 19
⁩ Community Oncology Research Program (NCORP) increases the generalizability of study findings,1100 access sites for ALL patients. Modernizing Clinical Trials for Patients With Cancer. | Oncology | JAMA | JAMA Network
Reply Retweet Like
PRECIS-2 retweeted
NIH Collaboratory 13 Dec 18
Thinking about submitting a grant application to for a ? We're happy to help! Check out our new chapter for some great tips.
Reply Retweet Like